NLRP4 Unlocks an NK/macrophages-centered Ecosystem to Suppress Non-small Cell Lung Cancer

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2025 Mar 15

PMID 40087771

Authors

Zhouwenli Meng

Jian Li

Hui Wang

Zhengqi Cao

Wenqing Lu

Xiaomin Niu

Yi Yang

Ziming Li

Ying Wang

Shun Lu

Affiliations

Soon will be listed here.

Abstract

Background: Tumor immune evasion extends beyond T cells, affecting innate immune elements like natural killer cells (NK) and macrophages within the tumor-immune microenvironment (TIME). Nevertheless, translational strategies to trigger collaboration of NK cells and macrophages to initiate sufficient anti-tumor cytoxicity remain scarce and are urgently needed.

Methods: In this study, TCGA datasets was used to confirm the prognosis value of the expression level of NLR family pyrin domain containing 4 (NLRP4) in NSCLC and the tumor tissues microarray was used to further check its clinical-relevance at protein-level. Subsequently, a tumor cell line with stable NLRP4 overexpression was established and subcutaneous tumor models in C57BL/6J mice were used to validate the anti-tumor characteristics of NLRP4. After analyzing the tumor microenvironment using flow cytometry and multiplex immunofluorescence, we further validated our findings through co-culture transwell assays and TCGA analysis. Utilizing bulk-RNA sequencing, proteomics, and mass spectrometry of mouse tumor tissues, we innovatively identified the downstream pathways of NLRP4 and verified them through co-immunoprecipitation (co-IP) and Western blot (WB) experiments.

Results: NLRP4 could trigger a distinct anti-tumor ecosystem organized by TIGITTNFA NK and iNOS M1 in lung cancer, discovered in TCGA analysis and verified in murine model. NLRP4-eco exerted tumor-suppression capacity through chemokine reprogramming including CCL5 and CXCL2. Meanwhile, the cytoxicity of NK could be facilitated by iNOSM1. Mechanistically, NLRP4 stimulated PI3K/Akt-NF-kB axis through suppression of the activity of PP2A. Besides, knockdown of CCL5 and blockade of CXCL2-CXCR2 axis abolished chemotaxis of TIGITTNFA NK and iNOS M1 respectively, as well as for LB-100, a PP2A inhibitor.

Conclusion: Altogether, we delineated NLRP4's unexplored facets and discovered an NLRP4-driven anti-tumor ecosystem composed of TIGITTNFA NK and iNOS M1. Finally, targeting PP2A by its inhibitor successfully mimicked the anti-tumor capacity of the overexpression of NLRP4.

References

Guo D, Ji X, Xie H, Ma J, Xu C, Zhou Y . Targeted Reprogramming of Vitamin B Metabolism as a Nanotherapeutic Strategy towards Chemoresistant Cancers. Adv Mater. 2023; 35(36):e2301257. DOI: 10.1002/adma.202301257. View

Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O . Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma. J Clin Invest. 2023; 133(6). PMC: 10014104. DOI: 10.1172/JCI164809. View

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023; 22(1):40. PMC: 9942077. DOI: 10.1186/s12943-023-01740-y. View

Oliveira G, Wu C . Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023; 23(5):295-316. PMC: 10773171. DOI: 10.1038/s41568-023-00560-y. View

Li G, Choi J, Kryczek I, Sun Y, Liao P, Li S . Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 2023; 41(2):304-322.e7. PMC: 10286807. DOI: 10.1016/j.ccell.2022.12.008. View

Zhu G, Tang Z, Huang R, Qu W, Fang Y, Yang R . CD36 cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023; 9(1):25. PMC: 9988869. DOI: 10.1038/s41421-023-00529-z. View

Bancaro N, Cali B, Troiani M, Elia A, Arzola R, Attanasio G . Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer Cell. 2023; 41(3):602-619.e11. DOI: 10.1016/j.ccell.2023.02.004. View

Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A . T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023; 186(7):1432-1447.e17. PMC: 10994488. DOI: 10.1016/j.cell.2023.03.007. View

Lu Y, Sun Q, Guan Q, Zhang Z, He Q, He J . The XOR-IDH3α axis controls macrophage polarization in hepatocellular carcinoma. J Hepatol. 2023; 79(5):1172-1184. DOI: 10.1016/j.jhep.2023.06.022. View

10.

Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y . Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023; 41(2):272-287.e9. DOI: 10.1016/j.ccell.2023.01.001. View

11.

Sen Santara S, Lee D, Crespo A, Hu J, Walker C, Ma X . The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature. 2023; 616(7956):348-356. PMC: 10165876. DOI: 10.1038/s41586-023-05912-0. View

12.

Cheng X, Wang H, Wang Z, Zhu B, Long H . Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023; 16(1):71. PMC: 10324139. DOI: 10.1186/s13045-023-01473-x. View

13.

Luca B, Steen C, Matusiak M, Azizi A, Varma S, Zhu C . Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell. 2021; 184(21):5482-5496.e28. PMC: 8526411. DOI: 10.1016/j.cell.2021.09.014. View

14.

Ma L, Heinrich S, Wang L, Keggenhoff F, Khatib S, Forgues M . Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer. Nat Commun. 2022; 13(1):7533. PMC: 9729309. DOI: 10.1038/s41467-022-35291-5. View

15.

Kirchhammer N, Trefny M, Natoli M, Brucher D, Smith S, Werner F . NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Sci Transl Med. 2022; 14(653):eabm9043. DOI: 10.1126/scitranslmed.abm9043. View

16.

Bill R, Wirapati P, Messemaker M, Roh W, Zitti B, Duval F . macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023; 381(6657):515-524. PMC: 10755760. DOI: 10.1126/science.ade2292. View

17.

Hwang H, Lee Y, Kang D, Lee H, Seo H, Ryu J . Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells. Cancer Lett. 2020; 490:100-110. DOI: 10.1016/j.canlet.2020.06.019. View

18.

de Masson A, Darbord D, Dobos G, Boisson M, Roelens M, Ram-Wolff C . Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients. Blood. 2021; 139(12):1820-1832. DOI: 10.1182/blood.2021013341. View

19.

Propper D, Balkwill F . Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19(4):237-253. DOI: 10.1038/s41571-021-00588-9. View

20.

Pan K, Farrukh H, Chittepu V, Xu H, Pan C, Zhu Z . CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022; 41(1):119. PMC: 8969382. DOI: 10.1186/s13046-022-02327-z. View